CP-601932

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameCP-601932
Drug Alias NameCP-601932
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinic acetylcholine receptor alpha4/beta2/alpha5 antagonistsNeuronal acetylcholine receptor; alpha3/beta4 antagonists
TargetsNicotinic acetylcholine receptor alpha4/beta2/alpha5Neuronal acetylcholine receptor; alpha3/beta4
Therapy Area/IndicationsMental Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsMental Disorders

Other Information

ATC CodeN/A
Related LinksN/A